UK study counts how many preterm babies get eylea for eye disease
NCT ID NCT06315556
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study collects data from UK preterm babies with retinopathy of prematurity (ROP) who are treated with the drug aflibercept (Eylea) using a paediatric dosing device. The main goal is to count how many babies receive this treatment and decide if there are enough to run a future long-term safety study. No extra visits or tests are needed—only existing hospital records are used.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aflibercept (Eylea)
What this could lead to
If enough babies are treated, this study could pave the way for a larger safety study on long-term effects of Eylea in preterm infants with ROP.
What could go wrong
This is an observational study that only counts cases and describes patient traits—it does not test whether the treatment works or is safe. The number of treated babies may be too small to proceed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRETERM INFANTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Many locations
RECRUITINGMultiple Locations, United Kingdom